Works Cited

1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts. Available at https://seer.cancer.gov/statfacts. Last accessed December 19, 2019.

2. U.S. Department of Health and Human Services. Healthy People 2020: Cancer Objectives. Available at https://www.healthypeople.gov/2020/topics-objectives/topic/cancer/objectives. Last accessed December 19, 2019.

3. U.S. Department of Health and Human Services. Healthy People 2010 Final Review. Available at https://www.cdc.gov/nchs/healthy_people/hp2010/hp2010_final_review.htm. Last accessed December 19, 2019.

4. Klabunde C, Brown M, Ballard-Barbash R, et al. Cancer screening—United States, 2010. MMWR. 2012;61(03):41-45.

5. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA. 2019;69(3):184-210.

6. Sabatino SA, White MC, Thompson TD, et al. Cancer screening test use—United States, 2013. MMWR. 2015;64(17):464-468.

7. Clarke T, Soler-Vila H, Fleming LE, Christ SL, Lee DJ, Arheart KL. Trends in adherence to recommended cancer screening: the U.S population and working cancer survivors. Front Oncol. 2012;2:190.

8. Wilson J, Gungner G. The Principles and Practice of Screening for Disease. Geneva: World Health Organization; 1968.

9. National Cancer Institute. Cancer Screening Overview (PDQ) – Health Professional Version. Available at https://www.cancer.gov/about-cancer/screening/hp-screening-overview-pdq. Last accessed December 19, 2019.

10. Wegwarth O, Schwartz LM, Woloshin S, et al. Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. Ann Intern Med. 2012;156(5):340-349.

11. Yabroff K, Klabunde CN, Yuan G, et al. Are physicians' recommendations for colorectal cancer screening guideline-consistent? J Gen Intern Med. 2011;26(2):177-184.

12. Holden D, Jonas DE, Porterfield DS, Reuland D, Harris R. Systematic review: enhancing the use and quality of colorectal cancer screening. Ann Intern Med. 2010;152(10):668-676.

13. Bowen D, Hannon PA, Harris JR, Martin DP. Prostate cancer screening and informed decision-making: provider and patient perspectives. Prostate Cancer Prostatic Dis. 2011;14(2):155-161.

14. Klabunde C, Marcus PM, Han PKJ, et al. Lung cancer screening practices of primary care physicians: results from a national survey. Ann Fam Med. 2012;10(2):102-110.

15. Kadivar H, Goff BA, Phillips WR, et al. Nonrecommended breast and colorectal cancer screening for young women: a vignette-based survey. Am J Prev Med. 2012;43(3):231-239.

16. Perkins R, Anderson BL, Sheinfeld Gorin S, Schulkin JA. Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists. Am J Prev Med. 2013;45(2):175-181.

17. Stewart S, Rim SH, Gelb CA. Physician knowledge and awareness of CA-125 as a screen for ovarian cancer in the asymptomatic, average-risk population. Health Educ Behav. 2012;39(1):57-66.

18. Baldwin L, Trivers KF, Matthews B, et al. Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med. 2012;156(3):182-194.

19. Han P, Klabunde CN, Breen N, et al. Multiple clinical practice guidelines for breast and cervical cancer screening: perceptions of US primary care physicians. Med Care. 2011;49(2):139-148.

20. Meguerditchian A, Dauphinee D, Girard N, et al. Do physician communication skills influence screening mammography utilization? BMC Health Serv Res. 2012;12:219.

21. Ferrante J, Fyffe DC, Vega ML, et al. Family physicians' barriers to cancer screening in extremely obese patients. Obesity (Silver Spring). 2010;18(6):1153-1159.

22. Alexandraki I, Mooradian AD. Barriers related to mammography use for breast cancer screening among minority women. J Natl Med Assoc. 2010;102(3):206-218.

23. Young R, Schwartz K, Booza J. Medical barriers to mammography screening of African American women in a high cancer mortality area: implications for cancer educators and health providers. J Cancer Educ. 2011;26(2):262-269.

24. Palmer R, Chhabra D, McKinney S. Colorectal cancer screening adherence in African-American men and women 50 years of age and older living in Maryland. J Community Health. 2011;36(4):517-524.

25. Guessous I, Dash C, Lapin P, et al. Colorectal cancer screening barriers and facilitators in older persons. Prev Med. 2010;50(1-2): 3-10.

26. Nodora J, Martz WD, Ashbeck EL, et al. Primary care physician compliance with colorectal cancer screening guidelines. Cancer Causes Control. 2011;22(9):1277-1287.

27. Li J, Berkowitz Z, Richards RB, Richardson LC. Shared decision making in prostate-specific antigen testing with men older than 70 years. J Am Board Fam Med. 2013;26(4):401-408.

28. Yeazel M, Oeffinger KC, Gurney JG, et al. The cancer screening practices of adult survivors of childhood cancer. Cancer. 2004;100(3):631-640.

29. Henderson T, Hlubocky FJ, Wroblewski KE, et al. Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: a mailed survey of pediatric oncologists. J Clin Oncol. 2010;28(5):873-883.

30. Burton-Chase A, Hovick SR, Sun CC, et al. Gynecologic cancer screening and communication with healthcare providers in women with Lynch syndrome. Clin Genet. 2014;86(2):185-189.

31. Levy B, Daly JM, Schmidt EJ, Xu Y. The need for office systems to improve colorectal cancer screening. J Prim Care Community Health. 2012;3(3):180-186.

32. Oliveria S, Heneghan MK, Halpern AC, et al. Communication about family members' risk of melanoma: self-reported practices of dermatologists in the United States. Arch Dermatol. 2012;148(5):621-627.

33. Volk R, Linder SK, Kallen MA, et al. Primary care physicians' use of an informed decision-making process for prostate cancer screening. Ann Fam Med. 2013;11(1):67-74.

34. Zapka J, Klabunde CN, Taplin S, et al. Screening colonoscopy in the U.S.: attitudes and practices of primary care physicians. J Gen Intern Med. 2012;27(9):1150-1158.

35. Han P, Kobrin S, Breen N, et al. National evidence on the use of shared decision making in prostate-specific antigen screening. Ann Fam Med. 2013;11(4):306-314.

36. Klabunde C, Frame PS, Meadow A, et al. A national survey of primary care physicians' colorectal cancer screening recommendations and practices. Prev Med. 2003;36(3):352-362.

37. Henderson S, DeGroff A, Richards TB, et al. A qualitative analysis of lung cancer screening practices by primary care physicians. J Community Health. 2011;36(6):949-956.

38. Hinz E, Kudesia R, Rolston R, et al. Physician knowledge of and adherence to the revised breast cancer screening guidelines by the United States Preventive Services Task Force. Am J Obstet Gynecol. 2011;205(3):201.

39. Chapman K, Nicholls K, Sullivan MM, et al. Colorectal cancer screening practices in Alabama: a survey of primary care physicians. J Cancer Educ. 2012;27(4):687-694.

40. Smith R, Brooks D, Cokkinides V, Salsow D, Brawley OW. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013;63(2):88-105.

41. Miller J, King JB, Joseph DA, Richardson LC. Breast cancer screening among adult women—Behavioral Risk Factor Surveillance System, United States, 2010. MMWR. 2012;61(Suppl 02):46-50.

42. Zhao G, Okoro CA, Li J, Town M. Health insurance status and clinical cancer screenings among U.S. adults. Am J Prev Med. 2018;54(1):e11-e19.

43. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.

44. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. NEJM. 2013;369(12):1106-1114.

45. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. NEJM. 2013;369(12):1095-1105.

46. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134.

47. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913.

48. Aberle D, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.

49. Bach P, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418-2429.

50. Welch H, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-613.

51. Albert R, Clark MM. Cancer screening in the older patient. Am Fam Physician. 2008;78(12):1369-1374.

52. Walter L, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285(21):2750-2756.

53. Lee S, Boscardin WJ, Stijacic-Cenzer I, et al. Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark. BMJ. 2013;346:e8441.

54. National Comprehensive Cancer Network. Breast Cancer Screening and Diagnosis: Version 1.2019. Available at https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf. Last accessed December 19, 2019.

55. American College of Obstetricians and Gynecologists. Breast cancer risk assessment and screening in average-risk women. Practice Bulletin No. 179. Obstet Gynecol. 2017;130:e1-e16.

56. Lee C, Dershaw D, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7(1):18-27.

57. U.S. Preventive Services Task Force. Final Recommendation Statement: Breast Cancer: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/breast-cancer-screening1. Last accessed December 19, 2019.

58. Qaseem A, Lin JS, Mustafa RA, Horwitch CA, Wilt TJ. Screening for breast cancer in average-risk women: a guidance statement from the American College of Physicians. Ann Intern Med. 2019;170(8):547-560.

59. Qaseem A, Lin JS, Mustafa RA, Horwitch CA, Wilt TJ. Screening for breast cancer in average-risk women: a guidance statement from the American College of Physicians. Ann Intern Med. 2019;170(8):547-560.

60. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015;314(15):1599-614.

61. Pitman JA, McGinty GB, Soman RR, Drotman MB, Reichman MB, Arleo EK. Screening mammography for women in their 40s: the potential impact of the American Cancer Society and U.S. Preventive Services Task Force breast cancer screening recommendations. AJR Am J Roentgenol. 2017;209(3):697-702.

62. Webb M, Cady B, Michaelson JS, et al. A failure analysis of invasive breast cancer: most deaths from disease occur in women not regularly screened. Cancer. 2014;120(18):2839-2846.

63. Mandelblatt J, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738-747.

64. Wang L, Kruper L. Mammography Screening Intervals May Affect Breast Cancer Prognosis. Presented at: Radiological Society of North America Annual Meeting; December 4, 2013; Chicago, IL.

65. Vinnicombe S, Pinto Pereira SM, McCormack VA, et al. Full-field digital versus screen-film mammography: comparison within the UK breast screening program and systematic review of published data. Radiology. 2009;251(2):347-358.

66. Souza F, Wendland EM, Rosa MI, Polanczyk CA. Is full-field digital mammography more accurate than screen-film mammography in overall population screening? A systematic review and meta-analysis. Breast. 2013;22(3):217-224.

67. American College of Radiology. Breast Cancer Screening: ACR Appropriateness Criteria. Available at https://acsearch.acr.org/docs/70910/Narrative. Last accessed December 19, 2019.

68. Gartlehner G, Thaler K, Chapman A, et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev. 2013;4:CD009632.

69. Nelson A. Controversies regarding mammography, breast self-examination, and clinical breast examination. Obstet Gynecol North Am. 2013;40(3):413-427.

70. Bobo J, Lee NC, Thames SF. Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst. 2000;92(12):971-976.

71. American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. Available at http://www.cancer.org/cancer/cancerbasics/lifetime-probability-of-developing-or-dying-from-cancer. Last accessed December 19, 2019.

72. Gail M, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.

73. Claus E, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer. 1994;73(3):643-651.

74. Berry D, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20(11):2701-2712.

75. Antoniou A, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98(8):1457-1466.

76. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111-1130.

77. Nelson H, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156(9):635-648.

78. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2020. Available at https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Last accessed December 19, 2019.

79. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329-1333.

80. Giardiello F, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119(6):1447-1453.

81. Win A, Lindor NM, Jenkins MA. Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Res. 2013;15(2):R27.

82. Tan M, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400-407.

83. Wu C, Shete S, Amos CI, Strong LC. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res. 2006;66(16):8287-8292.

84. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal. Version 3.2019. Available at https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Last accessed December 19, 2019.

85. Nothacker M, Duda V, Hahn M, et al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. BMC Cancer. 2009;9:335.

86. Mahoney M, Newell MS. Screening MR imaging versus screening ultrasound: pros and cons. Magn Reson Imaging Clin North Am. 2013;21(3):495-508.

87. Berg W, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307(13):1394-1404.

88. Warner E, Messersmith H, Causer P, et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 2008;148(9):671-679.

89. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. NEJM. 2012;367(21):1998-2005.

90. Duffy S, Chen TH, Smith RA, Yen AM, Tabar L. Real and artificial controversies in breast cancer screening. Breast Cancer Manage. 2013;2(6):519-528.

91. Moss S, Cuckle H, Evans A, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet. 2006;368(9552):2053-2060.

92. Mukhtar T, Yeates DRG, Goldacre MJ. Breast cancer mortality trends in England and the assessment of the effectiveness of mammography screening: population-based study. J Roy Soc Med. 2013;106(6):234-242.

93. Howard D, Ekwueme DU, Gardner JG, et al. The impact of a national program to provide free mammograms to low-income, uninsured women on breast cancer mortality rates. Cancer. 2010;116(19):4456-4462.

94. Nelson H, Tyne K, Naik A, et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727-737.

95. Gøtzsche P, Jørgensen K. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;6:CD001877.

96. Berry D, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. NEJM. 2005;353(17):1784-1792.

97. Kalager M, Adami HO, Bretthauer M, et al. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med. 2012;156(7):491-499.

98. International Agency for Research on Cancer. IARC World Cancer Report 2014. Available at http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014. Last accessed December 19, 2019.

99. Yaffe M, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. Radiology. 2011;258(1):98-105.

100. Fletcher S. Breast cancer screening: a 35-year perspective. Epidemiol Rev. 2011;33:165-175.

101. Bond M, Pavey T, Welch K, et al. Systematic review of the psychological consequences of false-positive screening mammograms. Health Technol Assess. 2013;17(13):1-170.

102. Kadivar H, Goff BA, Phillips WR, et al. Guideline-inconsistent breast cancer screening for women over 50: a vignette-based survey. J Gen Intern Med. 2014;29(1):82-89.

103. Benard V, Saraiya MS, Soman A, et al. Cancer screening practices among physicians in the National Breast and Cervical Cancer Early Detection Program. J Women's Health. 2011;20(10):1479-1484.

104. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147-172.

105. U.S. Preventive Services Task Force. Final Recommendation Statement: Cervical Cancer: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/cervical-cancer-screening2. Last accessed December 19, 2019.

106. Kulasingam SL HL, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2011.

107. Sawaya G, McConnell KJ, Kulasingnam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. NEJM. 2003;349(16):1501-1509.

108. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;320(7):674-686.

109. Massad L, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121(4):829-846.

110. National Cancer Institute. Diethylstilbestrol (DES) and Cancer. Available at https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/des-fact-sheet. Last accessed December 19, 2019.

111. Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev. 2013;2:35.

112. Berkowitz Z, Saraiya M, Sawaya GF. Cervical cancer screening intervals, 2006 to 2009: moving beyond annual testing. JAMA Intern Med. 2013;173(10):922-924.

113. National Comprehensive Cancer Network. Colorectal Cancer Screening. Version 2.2019. Available at https://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf. Last accessed December 19, 2019.

114. Kepka D, Breen N, King JB, Benard VB, Saraiya M. Overuse of Papanicolaou testing among older women and among women without a cervix. JAMA Intern Med. 2014;174(2):293-296.

115. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570-1595.

116. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016;315(23):2564-2575.

117. Rex D, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104(3):739-750.

118. Qaseem A, Denberg TD, Hopkins RH, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med. 2012;156(5):376-386.

119. Lieberman D, Rex DK, Winawer, SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2012;143(3):844-857.

120. Meyerhardt J, Mangu PB, Flynn PJ, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2013;31(35):4465-4470.

121. American College of Radiology. Colorectal Cancer Screening: ACR Appropriateness Criteria. Available at https://acsearch.acr.org/docs/69469/Narrative. Last accessed December 19, 2019.

122. Klabunde C, Joseph DA, King JB, White A, Plescia M. Vital signs: colorectal cancer screening test use—United States, 2012. MMWR. 2013;62(44):881-888.

123. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee opinion no. 482: colonoscopy and colorectal cancer screening strategies. Obstet Gynecol. 2011;117(3):766-771.

124. Zapka J, Klabunde CN, Arora NK. Physicians' colorectal cancer screening discussion and recommendation patterns. Cancer Epidemiol Biomarkers Prev. 2011;20(3):509-521.

125. Schoen R, Pinsky PF, Weissfeld JL, et al. Colorectal cancers not detected by screening flexible sigmoidoscopy in the prostate, lung, colorectal, and ovarian cancer screening trial. Gastrointest Endosc. 2012;75(3):612-620.

126. van Rossum L, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135(1):82-90.

127. Wong C, Fedorak RN, Prosser CI, et al. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int J Colorectal Dis. 2012;27(12):1657-1664.

128. Holme Ø, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev. 2013;9:CD009259.

129. Zauber A, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. NEJM. 2012;366(8):687-696.

130. Trombold J, Farmer RW, McCafferty M. The impact of colorectal cancer screening in a veteran hospital population. Am Surg. 2103;79(3):296-300.

131. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007;1:CD001216.

132. Levin T, Corley DA. Colorectal-cancer screening—coming of age [editorial]. NEJM. 2013;369(12):1164-1166.

133. Cronin KA, Lake AJ, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785-2800.

134. Whitlock E, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(9):638-658.

135. Robinson C, Cassells AN, Green MA, et al. Barriers to colorectal cancer screening among publicly insured urban women: no knowledge of tests and no clinician recommendation. J Natl Med Assoc. 2011;103(8):746-753.

136. Klabunde C, Lanier D, Nadel MR, et al. Colorectal cancer screening by primary care physicians: recommendations and practices, 2006–2007. Am J Prev Med. 2009;37(1):8-16.

137. Nadel M, Berkowitz Z, Klabunde CN, et al. Fecal occult blood testing beliefs and practices of U.S. primary care physicians: serious deviations from evidence-based recommendations. J Gen Intern Med. 2010;25(8):833-839.

138. Melamed M, Flehinger BJ, Zaman MB, et al. Screening for early lung cancer: results of the Memorial Sloan-Kettering study in New York. Chest. 1984;86(1):44-52.

139. Tockman M. Survival and mortality from lung cancer in a screened population. The Johns Hopkins Study. Chest. 1986;89(4):324S-325S.

140. Fontana R, Sanderson DR, Woolner LB, et al. Lung cancer screening: the Mayo program. J Occup Med. 1986;28(8):746-750.

141. U.S. Preventive Services Task Force. Lung Cancer: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening. Last accessed December 19, 2019.

142. IASLC Issues Statement on Lung Cancer Screening with Low-Dose Computed Tomography. Available at https://www.iaslc.org/About-IASLC/News-Detail/iaslc-issues-statement-on-lung-cancer-screening-with-low-dose-computed-tomography. Last accessed December 19, 2019.

143. National Comprehensive Cancer Network. Lung Cancer Screening: Version 1.2020. Available at https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf. Last accessed December 19, 2019.

144. Detterbeck F, Lewis SZ, Dickemper R, Addrizzo-Harris DJ, Alberts MW. Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):7S-37S.

145. Humphrey L, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2013;159(6):411-420.

146. Ma J, Ward EM, Smith R, Jemal A. Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer. 2013;119(7):1381-1385.

147. Pinsky PF, Berg CD. Applying the National Lung Screening Trial eligibility criteria to the U.S. population: what percent of the population and of incident lung cancers would be covered? J Med Screen. 2012;19(3):154-156.

148. Wender R, Fontham E, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63(2):107-117.

149. Jaklitsch M, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012;144(1):33-38.

150. Samet J, Crowell R, Estepar RSJ, et al. Providing Guidance on Lung Cancer Screening to Patients and Physicians. Available at https://www.lung.org/assets/documents/lung-cancer/lung-cancer-screening-report.pdf. Last accessed December 19, 2019.

151. Jacobson F, Austin JH, Field JK, et al. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of the American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg. 2012;144(1):25-32.

152. Sobue T, Moriyama N, Kaneko M, et al. Screening for lung cancer with low-dose helical computed tomography: Anti-lung Cancer Association Project. J Clin Oncol. 2002;20(4):911-920.

153. Pastorino U, Bellomi M, Landoni C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet. 2003;362(9384):593-597.

154. Oken M, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306(17):1865-1873.

155. Manser R, Lethaby R, Irving LB, et al. Screening for lung cancer. Cochrane Database Syst Rev. 2013;6:CD001991.

156. Patz EJ, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174(2):269-274.

157. de Koning H, Plevritis S, Hazelton WD, et al. Benefits and Harms of Computed Tomography Lung Cancer Screening Programs for High-Risk Populations. Bethesda, MD: Agency of Healthcare Research & Quality; 2013.

158. Boiselle P, White CS, Ravenel JG. Computed tomographic screening for lung cancer: current practice patterns at leading academic medical centers. JAMA Intern Med. 2014;174(2):286-287.

159. Carter H, Albertsen PC, Barry MJ, et al. Early Detection of Prostate Cancer (2018): AUA Guideline. Available at https://www.auanet.org/guidelines/prostate-cancer-early-detection-guideline. Last accessed December 19, 2019.

160. Qaseem A, Barry MJ, Denberg TD, et al. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013;158(10):761-769.

161. Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol. 2012;30(24):3020-3025.

162. National Comprehensive Cancer Network. Prostate Cancer Early Detection: Version 2.2019. Available at https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Last accessed December 19, 2019.

163. Allan R, Sanderson H, Epstein JI. Correlation of minute (0.5 mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol. 2003;170(2):370-372.

164. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69:184-210.

165. Grossman DC, US Preventive Services Task Force. Screening for prostate cancer. US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913.

166. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract. 2003;16(2):95-101.

167. Andriole G, Crawford ED, Grubb RL III, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125-132.

168. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1:CD004720.

169. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167(7):449-455.

170. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.

171. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158(3):143-153.

172. National Cancer Institute. Prostate Cancer Screening. Available at https://progressreport.cancer.gov/detection/prostate_cancer. Last accessed December 19, 2019.

173. Hudson S, Ohman-Strickland P, Ferrante JM, et al. Prostate-specific antigen testing among the elderly in community-based family medicine practices. J Am Board Fam Med. 2009;22(3):257-265.

174. Drazer M, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011;29(13):1736-1743.

175. Bynum J, Song Y, Fisher E. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare. J Am Geriatr Soc. 2010;58(4):674-680.

176. Jaramillo E, Tan A, Yang L, Kuo Y-F, Goodwin JS. Variation among primary care physicians in prostate-specific antigen screening of older men [research letter]. JAMA. 2013;310(15):1622-1624.

177. So C, Kirby KA, Mehta K, et al. Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy. J Gen Intern Med. 2012;27(6):653-660.

178. Rethman M, Carpenter W, Cohen EEW, et al. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dental Assoc. 2010;141(5):509-520.

179. Brocklehurst P, Kujan O, O'Malley LA, et al. Screening programmes for the early detection and prevention of oral cancer. Cochrane Database Syst Rev. 2013;11:CD004150.

180. Moyer V. Screening for oral cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(1):55-60.

181. Walsh T, Liu JL, Brocklehurst P, et al. Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults. Cochrane Database Syst Rev. 2013;11:CD010173.

182. Applebaum E, Ruhlen TN, Kronenberg FR, Hayes C, Peters ES. Oral cancer knowledge, attitudes and practices: a survey of dentists and primary care physicians in Massachusetts. J Am Dent Assoc. 2009;140(4):461-467.

183. Reed S, Cartmell KB, Duffy NG, et al. Oral cancer preventive practices of South Carolina dentists and physicians. J Cancer Educ. 2010;25(2):166-1673.

184. American Cancer Society. Cancer Facts and Figures, 2019. Available at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf. Last accessed December 19, 2019.

185. Buys S, Partridge E, Black A, et al. PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305:2295-2303.

186. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee opinion no. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol. 2011;117(3):742-746.

187. Grossman DC. Screening for ovarian cancer. U.S. Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(6):588-594.

188. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Ovarian Cancer: Screening Treatment, and Followup. Bethesda, MD: National Institutes of Health; 1994.

189. U.S. Preventive Services Task Force. Final Recommendation Statement. Pancreatic Cancer: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/pancreatic-cancer-screening1. Last accessed December 19, 2019.

190. Shin E, Canto MI. Pancreatic cancer screening. Gastroenterol Clin North Am. 2012;41(1):142-157.

191. Brand R, Lerch MM, Rubinstein WS, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut. 2007;56(10):1460-1469.

192. Greer J, Brand RE. Screening for pancreatic cancer: current evidence and future directions. Gastroenterol Hepatol. 2007;3(12):929-938.

193. Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg. 2013;257(1):17-26.

194. Zubarik R, Gordon SR, Lidofsky SD, et al. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. Gastrointest Endosc. 2011;74(1):87-95.

195. Korsse SE, Harinck F, van Lier MG, et al. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet. 2013;50(1):59-64.

196. Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control. 2008;15(4):280-287.

197. U.S. Preventive Services Task Force. Skin Cancer: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/skin-cancer-screening2. Last accessed December 19, 2019.

198. American Academy of Family Physicians. Clinical Preventive Service Recommendation. Skin Cancer. Available at https://www.aafp.org/patient-care/clinical-recommendations/all/skin-cancer.html. Last accessed December 19, 2019.

199. Practical Dermatology. AADA Provides Input On Skin Cancer Screening Recommendation. Available at https://practicaldermatology.com/news/aada-provides-input-on-skin-cancer-screening-recommendation. Last accessed December 19, 2019.

200. Chen S, Bravata DM, Weil E, Olkin I. A comparison of dermatologists' and primary care physicians' accuracy in diagnosing melanoma: a systematic review. Arch Dermatol. 2001;137:1627-1634.

201. Garg A, Wang J, Reddy SB, et al. The Integrated Skin Exam film: an educational intervention to promote early detection of melanoma by medical students. J Am Acad Dermatol. 2014;70(1):115-119.

202. Goulart J, Quigley EA, Dusza S, et al. Skin cancer education for primary care physicians: a systematic review of published evaluated interventions. J Gen Intern Med. 2011;26(9):1027-1035.

203. Eide M, Asgari MM, Fletcher SW, et al. Effects on skills and practice from a web-based skin cancer course for primary care providers. J Am Board Fam Med. 2013;26(6):648-657.

204. Curiel-Lewandrowski C, Chen SC, Swetter SM. Screening and prevention measures for melanoma: is there a survival advantage? Curr Oncol Rep. 2012;14(5):458-467.

205. Aitken J, Elwood M, Baade PD, Youl P, English D. Clinical whole-body skin examination reduces the incidence of thick melanomas. Int J Cancer. 2010;126(2):450-458.

206. Breitbart E, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol. 2012;66(2):201-211.

207. Nelson R. Skin cancer screenings work. Dermatol World. 2011;8.

208. Geller A, Zhang Z, Sober AJ, et al. The first 15 years of the American Academy of Dermatology skin cancer screening programs: 1985–1999. J Am Acad Dermatol. 2003;48(1):34-41.

209. Federman D, Kravetz JD, Kirsner RS. Skin cancer screening by dermatologists: prevalence and barriers. J Am Acad Dermatol. 2002;46(5):710-714.

210. U.S. Preventive Services Task Force. Final Recommendation Statement Testicular Cancer: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/testicular-cancer-screening. Last accessed December 19, 2019.

211. AAFP. Screening for Testicular Cancer: Recommendation. Available at https://www.aafp.org/patient-care/clinical-recommendations/all/cw-testicular-cancer.html. Last accessed December 19, 2019.

212. Marcell AV, Wibbelsman C, Seigel WM, and the Committee on Adolescence. Male adolescent sexual and reproductive health care. Pediatrics. 2011;128(6):E1658-e1676.

213. Ilic D, Misso ML. Screening for testicular cancer. Cochrane Database Syst Rev. 2011;2:CD007853.

214. Sabatino S, Lawrence B, Elder R, et al. Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services. Am J Prev Med. 2012;43(1):97-118.

215. Kim J, Menon U. Pre- and postintervention differences in acculturation, knowledge, beliefs, and stages of readiness for mammograms among Korean American women. Oncol Nurs Forum. 2009;36(2):E80-E92.

216. Ackerson K, Greteback K. Factors influencing cancer screening practices of underserved women. J Am Acad Nurs Pract. 2007;19(11):591-601.

217. Williams K, Mabiso A, Todem D, et al. Differences in knowledge of breast cancer screening among African American, Arab American, and Latina women. Prev Chronic Dis. 2011;8(2):A20.

218. Nicholas J. Harmonizing lung cancer screening guidelines. J Natl Cancer Inst. 2012;104(20):1531-1532.

219. Torke A, Schwartz PH, Holtz LR, et al. Older adults and forgoing cancer screening: "I think it would be strange." JAMA Intern Med. 2013;173(7):526-531.

220. Torke A, Schwartz PH, Holtz LR, et al. Caregiver perspectives on cancer screening for persons with dementia: "Why put them through it?" J Am Geriatr Soc. 2013;61(8):1309-1314.

221. Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431.

222. Edwards B, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-573.

223. Jimbo M, Rana GK, Hawley S, et al. What is lacking in current decision aids on cancer screening? CA Cancer J Clin. 2013;63(3):193-214.

224. Anhang Price R, Zapka J, Edwards H, Taplin SH. Organizational factors and the cancer screening process. J Natl Cancer Inst Monogr. 2010;2010(40):38-57.

225. Sarfaty M, Myers RE, Harris DM, et al. Variation in colorectal cancer screening steps in primary care: basis for practice improvement. Am J Med Qual. 2012;27:458-466.

226. Meissner H, Klabunde CN, Han PK, et al. Breast cancer screening beliefs, recommendations and practices: primary care physicians in the United States. Cancer. 2011;117(14):3101-3111.

227. Meissner H, Tiro JA, Yabroff KR, Haggstrom DA, Coughlin SS. Too much of a good thing? Physician practices and patient willingness for less frequent Pap test screening intervals. Med Care. 2010;48:249-259.

228. Sifri R, Wender R, Lieberman D, et al. Developing a quality screening colonoscopy referral system in primary care practice: a report from the National Colorectal Cancer Roundtable. CA Cancer J Clin. 2010;60:40-49.

229. Meissner H, Breen N, Klabunde CN, et al. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2006;15:389-394.

230. Dietrich A, Tobin JN, Robinson CM, et al. Telephone outreach to increase colon cancer screening in Medicaid managed care organizations: a randomized controlled trial. Ann Fam Med. 2013;11(4):335-343.

231. Simon S, Zhang F, Soumerai SB, et al. Failure of automated telephone outreach with speech recognition to improve colorectal cancer screening: a randomized controlled trial. Arch Intern Med. 2010;170(3):264-270.

232. Slater J, Henly GA, Ha CN, et al. Effect of direct mail as a population-based strategy to increase mammography use among low-income underinsured women ages 40 to 64 years. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2346-2352.

233. Everett T, Bryant A, Griffin MF, et al. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev. 2011;5:CD002834.

234. Charlton M, Mengeling MA, Halfdanarson TR, et al. Evaluation of a home-based colorectal cancer screening intervention in a rural state. J Rural Health. 2014;30(3):322-332.

235. Gupta S, Halm EA, Rockey DC, et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. JAMA Intern Med. 2013;173(18):1725-1732.

236. Hoffman R, Steel SR, Yee EF, et al. A system-based intervention to improve colorectal cancer screening uptake. Am J Manage Care. 2011;17(1):49-55.

237. Tangka FKL, Howard DH, Royalty J, et al. Cervical cancer screening of underserved women in the United States: results from the National Breast and Cervical Cancer Early Detection Program, 1997–2012. Cancer Causes Control. 2015;26(5):671-686.

Evidence-Based Practice Recommendations Citations

1. U.S. Preventive Services Task Force. Breast Cancer: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/breast-cancer-screening1. Last accessed January 7, 2020.

2. U.S. Preventive Services Task Force. Cervical Cancer: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/cervical-cancer-screening2. Last accessed January 7, 2020.

3. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112(7):1016-1030. Available at https://www.asge.org/docs/default-source/education/practice_guidelines/piis0016510717318059.pdf?sfvrsn=e7e83550_0. Last accessed January 7, 2020.

4. National Comprehensive Cancer Network. Lung Cancer Screening: Version 1.2020. Available at https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf. Last accessed January 7, 2020.

5. U.S. Preventive Services Task Force. Oral Cancer: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/oral-cancer-screening1. Last accessed January 7, 2020.


Copyright © 2020 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.